LSTA
Lisata Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Lisata Therapeutics has 4 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceWe collaborated with the academic sponsor of the ASCEND trial, the Australasian Gastrointestinal Clinical Trials Group (AGITG) along with the University of Sydney to conduct the study at 25 sites in Australia and New Zealand.
LSTA 10-Kaccession 0000320017-26-000023
SentenceIn addition, certain preclinical data using certepetide in combination with antibody drug conjugates (ADCs) has been generated as part of our research collaboration with Catalent.
LSTA 10-Kaccession 0000320017-26-000023
SentencePursuant to the SBP License Agreement, which we assumed in connection with the Merger, SBP licensed to Cend the exclusive right to use certain patents to further Cend's research and development efforts relating to certepetide.
LSTA 10-Kaccession 0000320017-26-000023
SentenceWe collaborated with the academic sponsor of the ASCEND trial, the Australasian Gastrointestinal Clinical Trials Group (AGITG) along with the University of Sydney to conduct the study at 25 sites in Australia and New Zealand.
LSTA 10-Kaccession 0000320017-26-000023
SentenceRevenue totaled $0.2 million and $1.0 million for the years ended December 31, 2025 and 2024, in connection with certain upfront license fees in the current year and the Exclusive License and Collaboration Agreement with Kuva in the prior year.
LSTA 10-Kaccession 0000320017-26-000023
SentenceRevenue totaled $0.2 million and $1.0 million for the years ended December 31, 2025 and 2024, in connection with certain upfront license fees in the current year and the Exclusive License and Collaboration Agreement with Kuva in the prior year.
LSTA 10-Kaccession 0000320017-26-000023
SentenceIn consideration for the license, Qilu made an upfront payment of $10.0 million to Cend, which was recognized as revenue by Cend prior to our acquisition of Cend on September 15, 2022 (the "Cend Merger").
LSTA 10-Kaccession 0000320017-26-000023
—
Largest filed tie
—
Lisata Therapeutics, Inc.
1.04
Expected move
No implied move.